ConductScience.org, home

Paper9756776

Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.

Takei M and 4 others. Antimicrob Agents Chemother, 1998. Cited by 32 papers, by iCite.

Cite this record

ConductScience Library. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Papers, record 9756776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9756776

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
1998
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
32
iCite
Relative citation ratio, by iCite
0.99
iCite
Revised in PubMed
2020-07-24
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Takei MM
2Fukuda HH
3Yasue TT
4Hosaka MM
5Oomori YY

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Infective AgentsMajor topic
BacteriaMajor topic
Enzyme InhibitorsMajor topic
FluoroquinolonesMajor topic
Topoisomerase II InhibitorsMajor topic
Gatifloxacin
HeLa Cells
Humans

Source PubMed

Download CSV of topics

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
11963290Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II.Antimicrob Agents Chemother1990https://conductscience.org/library/papers/1963290PubMed
22556080Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2556080PubMed
31332587In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1332587PubMed
48517696Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/8517696PubMed
58227000Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions.J Biol Chem1993https://conductscience.org/library/papers/8227000PubMed
67904438Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus.Antimicrob Agents Chemother1993https://conductscience.org/library/papers/7904438PubMed
78203860In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/8203860PubMed
88092836Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/8092836PubMed
97997176Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.Mol Microbiol1994https://conductscience.org/library/papers/7997176PubMed
107826854Roles of DNA topoisomerases in chromosomal replication and segregation.Adv Pharmacol1994https://conductscience.org/library/papers/7826854PubMed
117872758Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition.Antimicrob Agents Chemother1994https://conductscience.org/library/papers/7872758PubMed
127783632The twisted 'life' of DNA in the cell: bacterial topoisomerases.Mol Microbiol1995https://conductscience.org/library/papers/7783632PubMed
138524852Topoisomerase IV is a target of quinolones in Escherichia coli.Proc Natl Acad Sci U S A1995https://conductscience.org/library/papers/8524852PubMed
147492103Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.Antimicrob Agents Chemother1995https://conductscience.org/library/papers/7492103PubMed
158723458Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus.Antimicrob Agents Chemother1996https://conductscience.org/library/papers/8723458PubMed
168843298
Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Antimicrob Agents Chemother1996https://conductscience.org/library/papers/8843298PubMed
178851598Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene.Antimicrob Agents Chemother1996https://conductscience.org/library/papers/8851598PubMed
189124828Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.Antimicrob Agents Chemother1996https://conductscience.org/library/papers/9124828PubMed
199278055Crystal structure of the breakage-reunion domain of DNA gyrase.Nature1997https://conductscience.org/library/papers/9278055PubMed
209293187DNA gyrase, topoisomerase IV, and the 4-quinolones.Microbiol Mol Biol Rev1997https://conductscience.org/library/papers/9293187PubMed

See all 29 referencesDownload CSV of references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.

PMIDTitleJournalYearIn PapersSource
40435237Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586.Sci Adv2025https://conductscience.org/library/papers/40435237PubMed
36417527Top2a promotes the development of social behavior via PRC2 and H3K27me3.Sci Adv2022https://conductscience.org/library/papers/36417527PubMed
35096778Design of a Controlled-Release Delivery Composite of Antibacterial Agent Gatifloxacin by Spherical Silica Nanocarrier.Front Chem2021https://conductscience.org/library/papers/35096778PubMed
29311442Usefulness of simultaneous and sequential monitoring of glucose level and electrocardiogram in monkeys treated with gatifloxacin under conscious and nonrestricted conditions.Exp Anim2018https://conductscience.org/library/papers/29311442PubMed
23357772Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.Antimicrob Agents Chemother2013https://conductscience.org/library/papers/23357772PubMed
12234876Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12234876PubMed
12121916Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide.Antimicrob Agents Chemother2002https://conductscience.org/library/papers/12121916PubMed
11790160Gatifloxacin: a review of its use in the management of bacterial infections.Drugs2002https://conductscience.org/library/papers/11790160PubMed
11709337Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11709337PubMed
11257024Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.Antimicrob Agents Chemother2001https://conductscience.org/library/papers/11257024PubMed
10582891Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.Antimicrob Agents Chemother1999https://conductscience.org/library/papers/10582891PubMed
10551438Gatifloxacin.Drugs1999https://conductscience.org/library/papers/10551438PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
TOP2A7153PubTator's text mininghttps://conductscience.org/library/genes/7153

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9756776

GET https://conductscience.org/api/papers/v1/9756776/references?page=2